Latest news with #AI-QCT
Business Wire
06-05-2025
- Health
- Business Wire
AI Meets Value-Based Care: Cleerly and Cardiac Care Alliance Join Forces to Revolutionize Heart Disease Detection
DENVER--(BUSINESS WIRE)-- Cleerly, the leader in cardiovascular imaging, and Cardiac Care Alliance, leader in value-based cardiovascular care solutions, today announced a strategic partnership to enhance cardiovascular care delivery across the healthcare ecosystem. This collaboration will integrate Cleerly's advanced AI-powered coronary artery assessment technology with Cardiac Care Alliance's cardiovascular care network. This collaboration will integrate Cleerly's advanced AI-powered coronary artery assessment technology with Cardiac Care Alliance's cardiovascular care network. Share As part of this partnership, Cardiac Care Alliance's offering to payers and practices will include Cleerly's Artificial Intelligence–Quantitative Coronary Tomography (AI-QCT) technology. The goal is to ensure symptomatic patients undergo Cleerly's noninvasive assessment, when appropriate, prior to cardiac catheterization procedures, helping direct the right patients to the catheterization laboratory while avoiding unnecessary testing and associated costs for others. The initiative will launch initially with cardiology practices in Texas, with plans for broader implementation. Cardiac Care Alliance improves access to care and reduces overall unnecessary spending through collaboration with cardiologists, primary care providers, patients, health systems, and payers, while Cleerly's AI-QCT technology provides comprehensive, standardized assessment of coronary artery disease based on noninvasive Cardiac Computed Tomography Angiography (CCTA). Studies comparing Cleerly's technology with invasive gold standards have demonstrated high accuracy in assessing the presence, extent, and composition of coronary atherosclerotic plaque, superior to consensus readings from Level 3 Expert Physician Readers 1. "We're always seeking ways to expand access to life-saving heart care, and by combining our networks, both organizations can reach more providers and patients," said Prakash Patel, MD, CEO and Chairman of Cardiac Care Alliance. "This partnership represents our commitment to providing solutions that are both clinically effective and economically sustainable. Cardiovascular disease currently costs the US healthcare system approximately $233 billion annually, and is the most costly chronic condition in the US, roughly 11% of total healthcare expenditures 2. Delivering care that can provide early detection and guide clinical decisions to the right interventions to improve outcomes and reduce unnecessary costs, are critical to addressing this growing healthcare challenge." "This collaboration with Cardiac Care Alliance marks Cleerly's first value-based care partnership, representing an important milestone in our mission to transform cardiovascular care," said Dr. James Min, founder and CEO of Cleerly. "By detecting coronary artery disease with greater precision and more accurately through noninvasive means, we can help guide personalized care decisions that improve outcomes while reducing healthcare costs. With cardiovascular costs projected to increase to over $1 trillion by 2035 as the population ages 3, and hospital readmissions for cardiac conditions among the most common and costly within Medicare 4, we're strongly focused on the fact that many cardiovascular conditions are treatable when caught early, potentially saving countless lives." About Cleerly Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced noninvasive CT imaging. Cleerly's approach is grounded in science, based on millions of images from over 40,000 patients. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: About Cardiac Care Alliance Cardiac Care Alliance is revolutionizing cardiovascular care through an innovative, integrated, and partnership-driven model. By empowering providers, payers, health systems, and patients with timely access to high-quality care, patient outcomes are improved while optimizing costs. This value-based approach prioritizes quality and measurable health improvements. Cardiac Care Alliance is committed to proactive, personalized, and patient-centered care models that make cardiovascular healthcare more seamless, accessible, and coordinated. Through strategic partnerships, the alliance enhances care delivery, drives better outcomes, and creates sustainable, cost-effective solutions. To learn more, visit:
Yahoo
02-04-2025
- Health
- Yahoo
Cleerly CONFIRM2 study finds women with CAD at higher risk of MACE
Cleerly has announced interim results from a trial, described as the largest-ever cardiovascular phenotype outcomes study, finding that women living with chronic coronary artery disease (CAD) are at higher risk of major adverse coronary events (MACE) than men. The Cleerly CONFIRM2 trial was a retrospective and prospective, open-label trial that examined 3,551 patients to determine if AI-based Quantitative Computed Tomography (AI-QCT) could be used to predict mortality and MACE. By design, 49.5% of the trial population comprised of women. Results found that while the overall burden for CAD in the population studied fell mostly on men, women were at higher risk of developing MACE than men due to higher rates of plaque volume, calcified plaque, non-calcified plaque, and percentage atheroma volumes detected through AI-QCT. Lead researcher for the Cleerly study, Gudrun Feuchtner, spoke with Clinical Trials Arena shortly after unveiling the results at the 2025 American College of Cardiology's Annual Scientific Expo, arguing that the adoption of AI-QCT over traditional QCT could improve clinical outcomes for women. Feuchtner said: 'We had one main analysis, and we focused on the differences between men and women because heart disease is under-diagnosed in women and outcomes for women are worse. 'Currently in cardiology, we [have tools to measure] risk factors, but the performance of these [measurements] is very poor. AI analysis can more precisely stratify the different layers of atherosclerosis, so not only can we quantify calcium, but we can also quantify other components like calcified plaque, non-calcified plaque or lipid necrotic-rich core plaque, which puts an individual at even higher risk. In the trial, we found that these features enhance risk prediction in women more than men.' The Cleerly study, titled: 'AI-Quantitative CT Coronary Plaque Features Associate with a Higher Relative Risk in Women: CONFIRM2-Registry' joins research published in 2024, namely the CREDENCE (NCT02173275) and PACIFIC-1 (NCT01521468) studies, both of which also found Cleerly's AI Ischemia QCT system able to predict MACE in CAD patients. Elsewhere in the field of cardiac devices, Johnson & Johnson MedTech's Shockwave Medical has launched its Javelin Peripheral IVL Catheter in the US for peripheral artery disease (PAD). "Cleerly CONFIRM2 study finds women with CAD at higher risk of MACE" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
31-03-2025
- Health
- Yahoo
Cleerly Unveils Groundbreaking Late-Breaking Clinical Trial Results Demonstrating AI-QCT's Predictive Power for Women's Cardiovascular Risk at ACC.25
New Findings from the CONFIRM2 Registry Reveal Significant Gender Disparities in Coronary Plaque Features and Associated Risks for Major Adverse Cardiovascular Events DENVER, March 31, 2025--(BUSINESS WIRE)--Cleerly, the leader in cardiovascular AI imaging, has announced revolutionary findings from its late-breaking clinical trial presented at the American College of Cardiology's Annual Scientific Session + Expo (ACC.25) in Chicago, Illinois. The study, titled "Artificial Intelligence-based Quantitative Computed Tomography (AI-QCT) Coronary Plaque Features Predict Risk More Pronounced in Females: The International Multicentric Registry CONFIRM2," was led by Gudrun M. Feuchtner, MD, MBA, and presented during the Clinical and Investigative Horizons I session on March 31st, 2025. This research is simultaneously published today in Circulation: Cardiovascular Imaging, a peer-reviewed journal of the American Heart Association. The findings demonstrate that AI-QCT features of coronary artery disease (CAD), as detected by Cleerly's AI-QCT, can identify women at high risk for major adverse cardiovascular events (MACE) and improves risk stratification - a population that has historically been underdiagnosed and undertreated for CAD. The CONFIRM2 study is notable for including approximately 50% female participants and a diverse cohort of 3,500 individuals from 11 countries, highlighting the broad applicability of these findings in addressing cardiovascular health disparities. Key Findings on Gender Disparities in Cardiovascular Risk Higher Risk for Women: Despite a higher total AI-QCT CAD burden in men, similar increases in AI-QCT-derived plaque features (total plaque volume, calcified plaque, non-calcified plaque, and percentage atheroma volume) confer a significantly higher risk for MACE in women. Traditional risk scores performed poorly, while AI-QCT added significant predictive value for both sexes. Enhanced Detection and Risk Stratification: Cleerly's AI-QCT improves the detection and characterization of coronary atherosclerosis, offering more precise prognostic risk stratification for MACE that surpasses traditional risk factors. Gender-Specific Insights: AI-QCT reveals that certain coronary plaque features present a higher risk of MACE in women compared to men, emphasizing the need for tailored preventive strategies for women. Prognostic Value Consistency: The analysis shows that AI-QCT has strong prognostic value in both women and men, with stenosis and non-calcified plaque identified as the strongest independent predictors in women. Implications for Women's Heart Health These findings underscore the urgent unmet need to integrate AI-QCT into clinical practice for unbiased risk estimation in both men and women. Enhanced Precision & Personalization: Using AI-QCT-based risk stratification instead of traditional risk scores strongly enhances precision and enables tailored preventive care. Addressing Underdiagnosis & Undertreatment: Transitioning to an AI-QCT-based approach may eliminate bias and tackle the longstanding issue of underdiagnosis and undertreatment of CAD in women, ultimately improving outcomes. Increased Awareness & Tailored Therapies: AI-QCT's ability to identify higher risk in women should drive greater awareness and prompt reinforced anti-atherosclerotic therapies and other preventive measures tailored specifically to women. Potential for Sex-Specific Guidelines: These insights may lead to the development of sex-specific treatment guidelines, ensuring women receive the most appropriate and effective care for their cardiovascular health. "This research is a significant step forward in addressing the historical disparities in cardiovascular care for women. AI-QCT provides physicians with a powerful, unbiased tool that not only enhances detection but also enables more precise risk prediction and personalized care. These findings underscore the urgency of incorporating AI-QCT into clinical practice to improve outcomes for all patients, and especially for women," said Gudrun M. Feuchtner, MD, MBA, lead researcher of the study, from Medical University Innsbruck, Austria, on behalf of the CONFIRM2 investigator group led by Principal Investigator Alexander van Rosendael, MD, PhD, from Leiden University Medical Center and Ibrahim Danad, MD, from Radboud Medical University Center, Netherlands. About Cleerly Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced noninvasive CT imaging. Cleerly's approach is grounded in science, based on millions of images from over 40,000 patients. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: View source version on Contacts Cleerly Media Contact Christy Sievertpress@
Yahoo
27-03-2025
- Health
- Yahoo
Cleerly to Present Late-Breaking Clinical Trial Results on Cardiovascular Risk in Women at ACC.25
Cleerly to Present Late-Breaking Findings and Participate in Key ACC.25 Sessions DENVER, March 27, 2025--(BUSINESS WIRE)--Cleerly, the leader in cardiovascular AI imaging, announces its participation in the American College of Cardiology Annual Scientific Session + Expo (ACC.25) from March 29-31, 2025, at the McCormick Place Convention Center in Chicago, Illinois. Cleerly will share its late-breaking findings on Artificial Intelligence-based Quantitative Computed Tomography's (AI-QCT's) role in identifying risks of future major adverse cardiovascular events (MACE) in women. Onsite, Cleerly will demonstrate the company's AI-enabled coronary computed tomography angiography (CCTA) solution to help guide personalized prognosis, diagnosis, and treatment of coronary artery disease (CAD). Late-Breaking Clinical Trial Presentation In the session "Clinical and Investigative Horizons" on March 31st at 9:00 AM, Dr. Gudrun Feuchtner will present late-breaking clinical research titled "Artificial Intelligence-based Quantitative Computed Tomography (AI-QCT) Coronary Plaque Features Predict Risk More Pronounced in Females: The International Multicentric Registry CONFIRM2," on behalf of the CONFIRM2 investigators. This groundbreaking research will shine a light on the potential role of Cleerly's AI-QCT for measuring disease in women, in whom coronary artery disease is often underdiagnosed and undertreated. CONFIRM2 is one of the few studies in which about 50% of the participants are female. With a diverse trial population of 3,500 participants from sites across 11 countries, this study highlights the generalized applicability of the results in addressing cardiovascular health disparities. Sessions and Abstracts Cleerly's founder and CEO, Dr. James Min, will be featured on the Health Equity Panel on March 30th from 2:30 - 3:30 PM. This session, titled "Championing Communities of Health: A Cross-Industry Panel Discussion on Community Education, Cardiovascular Disease Prevention, and Screening Programs," will address critical issues surrounding health equity and the importance of community engagement in cardiovascular health. Cleerly will also participate in a Lounge & Learn Session titled "Increasing Female Physician Leadership in Clinical Trials" on March 30th from 1:00 - 1:30 PM in the Education Zone, Theater 1 of the Lounge and Learn Pavilion. Additionally, Cleerly will present six additional abstracts throughout the conference, showcasing advancements in heart health technology and research. Visit Cleerly at Booth #16033 Stop by and learn more about Cleerly at booth #16033, where a coffee bar with barista service will be available for all visitors. The Cleerly team will be available to demonstrate the technology, including its COMPARE feature, which enables clinicians to track the progression of plaque over time. Attendees can also stop by Cleerly's "Meet Cleerly Leadership" event on Sunday, March 30th from 12:30 to 1:30 PM, for an opportunity to talk with Cleerly leadership and enjoy a complimentary lunch-style buffet. To see a full schedule of Cleerly presentations or schedule a meeting with Cleerly leadership, please visit this link. About Cleerly Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced noninvasive CT imaging. Cleerly's approach is grounded in science, based on millions of images from over 40,000 patients. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: View source version on Contacts Cleerly Media Contact Christy Sievertpress@
